Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance

References

• Flores KF, Bandoli G, Chambers CD, Schatz M, Palmsten K. Asthma prevalence among women aged 18 to 44 in the United States: national health and nutrition examination survey 2001–2016. J Asthma. 2019;1–10.
   Web of Science ®Google Scholar
• California Breathing County Asthma Data Tool. California Department of Public Health; 2019. Available from: www.cdph.ca.gov/Programs/CCDPHP/DEODC/EHIB/CPE/Pages/CaliforniaBreathingCountyAsthmaProfiles.aspx. Accessed May 20, 2020.
   Google Scholar
• Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019;56(8):872–881. doi:10.1080/02770903.2018.1500584
   PubMed Web of Science ®Google Scholar
• Carr TF, Zeki AA, Kraft M. Eosinophilic and Noneosinophilic Asthma. Am J Respir Crit Care Med. 2018;197(1):22–37. doi:10.1164/rccm.201611-2232PP
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi:10.1164/rccm.200903-0392OC
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2017.
   Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2020.
   Google Scholar
• Martin RJ, Szefler SJ, King TS, et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007;119(1):73–80. doi:10.1016/j.jaci.2006.10.035
   PubMed Web of Science ®Google Scholar
• Johnson N, Varughese B, De La Torre MA, Surani SR, Udeani G. A review of respiratory biologic agents in severe asthma. Cureus. 2019;11(9):e5690. doi:10.7759/cureus.5690
   PubMed Web of Science ®Google Scholar
• Mepolizumab [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; 2019.
   Google Scholar
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:Cd010834.
   PubMed Web of Science ®Google Scholar
• Drick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18(1):119. doi:10.1186/s12890-018-0689-2
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Wardlaw AJ. Insights into the Pathogenesis of Asthma and Other Eosinophil-Mediated Diseases from Antagonists of Interleukin-5 and its ReceptorIn Chapter 15 - Antieosinophil Therapeutics. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. Boston: Academic Press; 2013:577–605.
   Google Scholar
• Varricchi G, Canonica GW. The role of interleukin 5 in asthma. Expert Rev Clin Immunol. 2016;12(9):903–905. doi:10.1080/1744666X.2016.1208564
   PubMed Web of Science ®Google Scholar
• Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–1309. doi:10.1093/intimm/dxp102
   PubMed Web of Science ®Google Scholar
• Possa SS, Leick EA, Prado CM, Martins MA, Tibério IFLC. Eosinophilic inflammation in allergic asthma. Front Pharmacol. 2013;4:46. doi:10.3389/fphar.2013.00046
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208
   PubMed Web of Science ®Google Scholar
• Efficacy and safety study of mepolizumab in subjects with severe hypereosinophilic syndrome (HES); Identifier NCT02836496. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine, US; July 19, 2016.
   Google Scholar
• Effect of mepolizumab in severe bilateral nasal polyps, Identifier NCT03085797. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); March 21, 2017.
   Google Scholar
• Fajt ML, Wenzel SE. Development of New Therapies for Severe Asthma. Allergy Asthma Immunol Res. 2017;9(1):3–14. doi:10.4168/aair.2017.9.1.3
   Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X
   PubMed Web of Science ®Google Scholar
• Kerr W, Harrison T, Loveday K, et al. P92 Effectiveness and safety of mepolizumab in real-world clinical practice: UK patient outcomes from the REALITI-A study. Horax. 2019;74:A140.
   Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e1747. doi:10.1016/j.jaci.2018.09.033
   PubMed Web of Science ®Google Scholar
• Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015–1027. doi:10.5414/CP202446
   PubMed Web of Science ®Google Scholar
• Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients, Identifier NCT02555371. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); September 21, 2015.
   Google Scholar
• A Phase 3a, repeat dose, open-label, long-term safety study of mepolizumab in asthmatic subjects, Identifier NCT02135692. ClinicalTrialsgov Bethesda, MD: National Library of Medicine (US); May 12, 2014.
   Google Scholar
• Safety profile - Mepolizumab for severe eosinophilic asthma. Available from: https://gskprocom/en-us/products/nucala/for-severe-eosinophilic-asthma/safety/. Accessed May 19, 2020.
   Google Scholar
• Summary of product characteristics (SmPC): mepolizumab (Nucala) 100 mg solution for injection in pre-filled syringe. EMC Electronic Medicines Compendium, UK. Available from: https://wwwmedicinesorguk/emc/product/10564/smpc. Accessed May 19, 2020.
   Google Scholar
• MotherToBaby pregnancy exposure registry. Available from: https://mothertobabyorg/ongoing-study/asthma/. Accessed May 19, 2020.
   Google Scholar
• A study to compare the pharmacokinetics of mepolizumab as a drug in a safety syringe or an autoinjector versus lyophilised drug, Identifier NCT03014674. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); January 9, 2017
   Google Scholar
• Study of mepolizumab autoinjector in asthmatics, Identifier NCT03099096. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US) April 4, 2017.
   Google Scholar
• Study of mepolizumab safety syringe in asthmatics, Identifier NCT03021304. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); January 13, 2017.
   Google Scholar
• Nucala (mepolizumab) gains FDA approval for two new self-administration options. GSK Press Releases; June 06, 2019. Available from: https://wwwgskcom/en-gb/media/press-releases/nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options. Accessed May 19, 2020.
   Google Scholar
• Mealey FH, Kenyon NJ, Avdalovic MV, Louie S. Difficult-to-control asthma in adults. Am J Med. 2007;120(9):760–763. doi:10.1016/j.amjmed.2006.10.015
   Web of Science ®Google Scholar
• Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. doi:10.1183/13993003.01046-2019
   PubMed Web of Science ®Google Scholar
• Denning DW, O’Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med. 2009;179(1):11–18. doi:10.1164/rccm.200805-737OC
   PubMed Web of Science ®Google Scholar
• Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab- Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128(1):210–212. doi:10.1016/j.jaci.2011.04.010
   Web of Science ®Google Scholar
• Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–1377. doi:10.1016/j.jaci.2007.09.032
   PubMed Web of Science ®Google Scholar
• Tan LD, Kenyon N, Yoneda KY, Louie S. Bronchial thermoplasty: implementing best practice in the era of cost containment. J Asthma Allergy. 2017;10:225–230. doi:10.2147/JAA.S135291
   Web of Science ®Google Scholar
• Prefilled Autoinjector: Instructions for Use - Nucala (mepolizumab) 100 mg/mL injection. Nucala website Available from: https://wwwnucalacom/content/dam/cf-pharma/nucala-v2/en_US/sea/pdf/NUCALA_Autoinjector_Instructions_for_Use.pdf. Accessed May 19, 2020.
   Google Scholar
• Tan L, Chupp G, Castro M, Kraft M. Going Beyond “Bio-markers”, Think “Life- markers”. CHEST. 2020;157(3):503–505. doi:10.1016/j.chest.2019.08.2210
   Web of Science ®Google Scholar
• Tan LD, Schaeffer B, Alismail A. Parasitic (Helminthic) infection while on asthma biologic treatment: not everything is what it seems. J Asthma Allergy. 2019;12:415–420. doi:10.2147/JAA.S223402
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2019.
   Google Scholar
• Bel EH, Bernstein DI, Bjermer L, et al. Usability of mepolizumab single-use prefilled syringe for patient self-administration. J Asthma. 2019;1–10.
   PubMed Web of Science ®Google Scholar
• Bernstein D, Pavord ID, Chapman KR, et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2019:1–12. doi:10.1080/02770903.2019.1630641
   Web of Science ®Google Scholar